Market News

Gilead Sciences (NASDAQ:GILD) Ticks Higher After Settling Patent Challenges

Gilead Sciences (NASDAQ:GILD) shares are ticking upwards after the healthcare major disclosed it has resolved litigation and patent challenges with major generic manufacturers including Lupin, Apotex, Macleods Pharma, Cipla, and Hetero Labs.

The challenges were related to Gilead’s Descovy, Vemlidy, and Odefsey. Under the agreements, Gilead has granted a non-exclusive license in the U.S. to the generic manufacturers for patents related to tenofovir alafenamide (Descovy and Vemlidy) starting October 31, 2031, and for Odefsey starting January 31, 2032.

The development implies that generic developers will be able to bring versions of these drugs on the market only after 2031 and 2032.

Read full Disclosure

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More